Literature DB >> 25290112

Phase variation in the modulation of the human immune response.

J Duchateau1, G Delespesse2, K Bolla3.   

Abstract

Entities:  

Year:  1983        PMID： 25290112     DOI： 10.1016/0167-5699(83)90028-2

Source DB:  PubMed          Journal:  Immunol Today        ISSN： 0167-5699


× No keyword cloud information.
  5 in total

1.  Prevention of recurrences in frequently relapsing herpes labialis with thymopentin. A randomized double-blind placebo-controlled multicenter study.

Authors:  K Bolla; D Djawari; E M Kokoschka; J Petres; S Lidén; R Gonseth; P Amblard; M G Bernengo; J J Bonerandi; A Claudy
Journal:  Surv Immunol Res       Date:  1985

2.  Thymopentin as adjuvant therapy to hepatitis B vaccination in formerly non-or hyporesponding hemodialysis patients.

Authors:  K Zàruba; P J Grob; K Bolla
Journal:  Surv Immunol Res       Date:  1985

Review 3.  Thymopentin and splenopentin as immunomodulators. Current status.

Authors:  V K Singh; S Biswas; K B Mathur; W Haq; S K Garg; S S Agarwal
Journal:  Immunol Res       Date:  1998       Impact factor: 2.829

4.  Potential interventions for novel coronavirus in China: A systematic review.

Authors:  Lei Zhang; Yunhui Liu
Journal:  J Med Virol       Date:  2020-03-03       Impact factor: 2.327

Review 5.  Treatments Administered to the First 9152 Reported Cases of COVID-19: A Systematic Review.

Authors:  David C Fajgenbaum; Johnson S Khor; Alexander Gorzewski; Mark-Avery Tamakloe; Victoria Powers; Joseph J Kakkis; Mileva Repasky; Anne Taylor; Alexander Beschloss; Laura Hernandez-Miyares; Beatrice Go; Vivek Nimgaonkar; Madison S McCarthy; Casey J Kim; Ruth-Anne Langan Pai; Sarah Frankl; Philip Angelides; Joanna Jiang; Rozena Rasheed; Erin Napier; Duncan Mackay; Sheila K Pierson
Journal:  Infect Dis Ther       Date:  2020-05-27
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.